

Mr John FAYET President
WORLD ANTI-DOPING AGENCY
Avenue Rhodanie 54

CH-1007 Lausanne

Neuville sur Sarthe, June 7, 2013.

Registered letter with acknowledgment

Mr. President,

The doctors in charge of the 39 teams that are members of MPCC met at our last meeting.

You can find the minutes of the meeting attached.

WADA in order to determine the prevalence of drug use in sport, has added to its monitoring program in 2011, substances not listed in the list of prohibitions. Tramadol hydrocodone, widely used in competition, belong to this group of substances. Is it possible to get the report of the monitoring and the resulting conclusions.

The side effects of Tramadol on vigilance are well established, as the team doctors of MPCC, asking the AMA to include tramadol in the list of prohibited competing products in the year 2014.

In this monitoring program, information on the use of outside competition glucocorticoids should also be collected. Can we be the recipients of the conclusions?

Doping in sport is primarily based on the misuse and abuse of newly developed and commercially available drugs.

The international fight against doping in sport has benefited from the collaboration between the Pharmaceutical Industry Research and authorities fight against doping, initiated by WADA.

The sharing of information on drugs at risk of misuse proved an undeniable effectiveness in the early development of detection methods (CERA)

Physicians adherent teams MPCC, meeting 7 February 2013, want collaboration with the pharmaceutical industry to go further.

They suggest that the new molecules that can be diverted from their use, are marked by the pharmaceutical industry before being placed on the market. This marking would have the advantage of a faster detection and indisputable in law

Convinced of the merits of our requests and waiting for your answer, believe, Mr. President, to express my best wishes.

Roger LEGEAY
MPCC President